Biodexa Pharmaceuticals Plc EBIT

The latest EBIT for BDRX is $-16M as of December 2025. That compares with $-6.6M in the prior-year period — down 140.1% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Biodexa Pharmaceuticals Plc's historical trend and sector peers before judging valuation or financial health.

Over the past year, BDRX's EBIT moved from $-6.6M to $-16M — a 140.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Biodexa Pharmaceuticals Plc's operating scale or balance-sheet position.

Against Healthcare companies, BDRX currently prints $-16M for EBIT, while the sector average sits near $23B. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at Biodexa Pharmaceuticals Plc's growth, margins, and balance sheet.

A EBIT figure of $-16M for BDRX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting BDRX's EBIT ($-16M), review year-over-year change from $-6.6M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.